These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21417007)

  • 21. Escape from immune- and nonimmune-mediated tumor surveillance.
    Malmberg KJ; Ljunggren HG
    Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure.
    Alexander S; Friedl P
    Trends Mol Med; 2012 Jan; 18(1):13-26. PubMed ID: 22177734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor-beta and the immune response to malignant disease.
    Teicher BA
    Clin Cancer Res; 2007 Nov; 13(21):6247-51. PubMed ID: 17975134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
    Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-mediated dormancy: an equilibrium with cancer.
    Teng MW; Swann JB; Koebel CM; Schreiber RD; Smyth MJ
    J Leukoc Biol; 2008 Oct; 84(4):988-93. PubMed ID: 18515327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment.
    Disis ML
    Clin Cancer Res; 2009 Nov; 15(21):6476-8. PubMed ID: 19861446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape.
    Egorov IK
    Cancer Immunol Immunother; 2006 Jan; 55(1):1-22. PubMed ID: 16091932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How do tumors actively escape from host immunosurveillance?
    Wilczyński JR; Duechler M
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):435-48. PubMed ID: 20922572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of immune escape of cancer and its regulation.
    Morita R; Hirohashi Y; Torigoe T
    Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397
    [No Abstract]   [Full Text] [Related]  

  • 31. Tumor immune escape mechanisms that operate during metastasis.
    Croci DO; Salatino M
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1923-36. PubMed ID: 21470132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppressive influences in the immune response to cancer.
    Bronte V; Mocellin S
    J Immunother; 2009 Jan; 32(1):1-11. PubMed ID: 19307988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dual effects of interleukin-18 in tumor progression.
    Park S; Cheon S; Cho D
    Cell Mol Immunol; 2007 Oct; 4(5):329-35. PubMed ID: 17976312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R; Emi M; Tanabe K; Uchida Y; Toge T
    Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic cells can escape the proapoptotic effects of TNF-α through increased autocrine IL-6/STAT3 signaling.
    Li S; Wang N; Brodt P
    Cancer Res; 2012 Feb; 72(4):865-75. PubMed ID: 22194466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T regulatory cells in cancer: recent advances and therapeutic potential.
    Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
    Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The immune system--is it relevant to cancer development, progression and treatment?
    Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How tumours escape mass destruction.
    Stewart TJ; Abrams SI
    Oncogene; 2008 Oct; 27(45):5894-903. PubMed ID: 18836470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor escape mechanisms in prostate cancer.
    Miller AM; Pisa P
    Cancer Immunol Immunother; 2007 Jan; 56(1):81-7. PubMed ID: 16362411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor immune escape mechanisms: impact of the neuroendocrine system.
    Lang K; Entschladen F; Weidt C; Zaenker KS
    Cancer Immunol Immunother; 2006 Jul; 55(7):749-60. PubMed ID: 16435128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.